MedTrace Logo

Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium

NCT03682497 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2020-05-01

No results posted yet for this study

Summary

This is a Phase I, Multicentre study to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium \[sK+\] during 28 days in Patients with HFmrEF or HFpEF and eGFR in the range of ≥40 and ≤70 mL/min/1.73m2.

Conditions

Interventions

DRUG

AZD9977

AZD9977 capsules taken orally for 28 days.

DRUG

Spironolactone

Spironolactone tablets taken orally for 28 days.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2020-03-31
Completion
2020-03-31

Countries

  • Bulgaria
  • Czechia
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03682497 on ClinicalTrials.gov